Showing results (51-60 of 242) with videos related to
Sort By:
Pageof 25
Cancer Cell|December 17, 2013
The evolution of tumor classification: a role for genomics?Paul A Bunn, Wilbur Franklin, Robert C DoebeleOncology (Williston Park, N.Y.)|January 24, 2006
Adjuvant chemotherapy for resected non-small-cell lung cancerBenjamin Solomon, John D Mitchell, Paul A BunnLung Cancer (Amsterdam, Netherlands)|March 25, 2018
Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapyBarbara A Helfrich, Dexiang Gao, Paul A BunnJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 14, 2020
HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved SurvivalAnastasios Dimou, Paul Grewe, John Sidney, et al.BMC Medical Genomics|July 30, 2022
PO2RDF: representation of real-world data for precision oncology using resource description frameworkYiqing Zhao, Anastasios Dimou, Feichen Shen, et al.Nature Reviews. Cancer|November 11, 2017
Small-cell lung cancer: what we know, what we need to know and the path forwardAdi F Gazdar, Paul A Bunn, John D MinnaSeminars in Oncology|July 3, 2002
Expression of target molecules in lung cancer: challenge for a new treatment paradigmFred R Hirsch, Wilbur A Franklin, Paul A BunnJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2014
Recent clinical advances in lung cancer managementDavid H Johnson, Joan H Schiller, Paul A BunnOncotarget|November 29, 2016
KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancerYayi He, Paul A Bunn, Caicun Zhou, et al.Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not knowDavid Raben, Barb Helfrich, Fortunato Ciardiello, et al.Pageof 25